Health Care Equities Analysis -- Research on Keryx Biopharma, Rigel Pharma,
Sanofi and Impax Laboratories
Editor Note: For more information about this release, please scroll to bottom.
LONDON, March 19, 2014
LONDON, March 19, 2014 /PRNewswire/ --
On Tuesday, March 18, 2014, the NASDAQ Composite ended at 4,333.31, up 1.25%,
the S&P 500 advanced 0.72% to 1,872.25, and the Dow Jones Industrial Average
closed at 16,336.19, up 0.55%. The gains were broad based as nine out of ten
sectors ended the session in positive. The S&P 500 Health Care Sector Index
finished the day at 688.96, up 1.17%, and the same has advanced 1.47% in the
last one month. Investor-Edge has initiated coverage on the following
equities: Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Rigel Pharmaceuticals
Inc. (NASDAQ: RIGL), Sanofi (NYSE: SNY) and Impax Laboratories Inc. (NASDAQ:
IPXL). Free technical research on KERX, RIGL, SNY and IPXL can be downloaded
upon signing up at:
On Tuesday, shares in Keryx Biopharmaceuticals Inc. surged 3.07% to close at
$15.45. A total of 1.45 million shares were traded, which is below the three
months average volume of 2.83 million. The company's shares oscillated between
$15.04 and $15.51 during the trading session. Keryx's shares has fallen by
0.96% in the last one month, while the same has gained 1.71% in the previous
three trading session and 19.31% on YTD basis. The company's shares are
trading above their 50-day and 200-day moving averages. Keryx
Biopharmaceuticals Inc.'s 50-day moving average of $15.04 is above the 200-day
moving average of $11.29. Furthermore, the company's stock is trading at the
Relative Strength Index (RSI) of 44.63. Sign up today to read free research on
Shares in Rigel Pharmaceuticals Inc. recorded a trading volume of 1.57 million
shares, as compared with a three months average volume of 1.12 million shares.
The stock ended the day at $4.70, up 5.62% after vacillating between $4.40 and
$4.80. Rigel Pharmaceuticals Inc.'s shares have rallied 17.21% in the previous
three trading sessions, 47.34% in the last one month, and 64.91% on YTD basis.
The company's shares are trading above their 50-day and 200-days moving
averages. Rigel Pharmaceuticals Inc.'s 50-day moving average of $3.46 is above
the 200-day moving average of $3.38. Additionally, shares of the company are
trading at the Relative Strength Index (RSI) of 62.85. Sign up today to read
free research on RIGL at:
On Tuesday, Sanofi's stock edged 0.68% higher, finishing the session at
$50.41. The stock recorded trading volume of 2.18 million shares as compared
to a three months average volume of 1.67 million shares. The stock fluctuated
between $50.21 and $50.68 during the session. Sanofi's shares have advanced
1.41% in the previous three trading session, while the same has fallen by
0.04% in the last one month and 6.00% on YTD basis. The company's shares are
trading below their 50-day and 200-day moving averages. Sanofi's 200-day
moving average of $51.20 is above the 50-day moving average of $50.46.
Moreover, the stock is trading at the Relative Strength Index (RSI) of 44.86.
Sign up today to read free research on SNY at:
Shares in Impax Laboratories Inc. saw a trading volume of 0.59 million shares,
as compared with a three months average volume of 0.57 million shares. The
stock ended the day at $27.84, down 0.25% and at an intraday range of $27.58
and $28.05. Shares of the company traded at a PE ratio of 28.84. Impax
Laboratories Inc.'s shares have gained 5.02% in the previous three trading
sessions, 16.88% in the last one month, and 10.74% on YTD basis. The stock is
trading above its 50-day and 200-day moving averages. Impax Laboratories
Inc.'s 50-day moving average of $24.76 is above the 200-day moving average of
$22.04. Furthermore, the stock is trading at the Relative Strength Index (RSI)
of 67.67. Sign up today to read free research on IPXL at:
1. This is not company news. We are an independent source and our views do not
reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts
basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only
human and are prone to make mistakes. If you notice any errors or omissions,
please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to
increase awareness for mentioned companies to our subscriber base and the
4. If you wish to have your company covered in more detail by our team, or
wish to learn more about our services, please contact us at pubco [at]
5. For any urgent concerns or inquiries, please contact us at compliance [at]
6. Are you a public company? Would you like to see similar coverage on your
company? Send us a full investors' package to research [at]
http://www.investor-edge.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Investor-edge. An
outsourced research services provider represented by Nidhi Vatsal, CFA, has
only reviewed the information provided by Investor-edge in this article or
report according to the Procedures outlined by Investor-edge. Investor-edge is
not entitled to veto or interfere in the application of such procedures by the
outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-edge makes no warranty, expressed or implied, as to the accuracy or
completeness or fitness for a purpose (investment or otherwise), of the
information provided in this document. This information is not to be construed
as personal financial advice. Readers are encouraged to consult their personal
financial advisor before making any decisions to buy, sell or hold any
securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-edge is not responsible for any error which may be occasioned at the
time of printing of this document or any error, mistake or shortcoming. No
liability is accepted by Investor-edge whatsoever for any direct, indirect or
consequential loss arising from the use of this document. Investor-edge
expressly disclaims any fiduciary responsibility or liability for any
consequences, financial or otherwise arising from any reliance placed on the
information in this document. Investor-edge does not (1) guarantee the
accuracy, timeliness, completeness or correct sequencing of the information,
or (2) warrant any results from use of the information. The included
information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Contact: CONTACT PERSON: Adam Redford, CONTACT PHONE: +852-8191-3972
Press spacebar to pause and continue. Press esc to stop.